RasGRP3, a Ras activator, contributes to signaling and the tumorigenic phenotype in human melanoma

Oncogene

Volumn 30, Issue 45, 2011, Pages 4590-4600

  Yang, D ^a   Tao, J ^a   Li, L ^a   Kedei, N ^a   Toth Z E ^b   Czap, A ^a   Velasquez, J F ^a   Mihova, D ^a   Michalowski, A M ^a   Yuspa, S H ^a   Blumberg, P M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Akt; cell transformation; guanine nucleotide exchange factor; HGF; melanoma; Ras activator

Indexed keywords

EPIDERMAL GROWTH FACTOR; PROTEIN KINASE B; RAS PROTEIN; SCATTER FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; CELL STRUCTURE; COLONY FORMATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; MELANOCYTE; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; CELL PROLIFERATION; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; GENE KNOCKDOWN TECHNIQUES; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HEPATOCYTE GROWTH FACTOR; HUMANS; MALE; MELANOMA; MICE; MICE, NUDE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 80755132201     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.166     Document Type: Article

References (54)

1. Ackermann J, Frutschi M, Kaloulis K, McKee T, Trumpp A, Beermann F. (2005). Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. Cancer Res 65: 4005-4011. (Pubitemid 40775636)
2. Aiba Y, Oh-hora M, Kiyonaka S, Kimura Y, Hijikata A, Mori Y et al. (2004). Activation of RasGRP3 by phosphorylation of Thr-133 is required for B cell receptor-mediated Ras activation. Proc Natl Acad Sci USA 101: 16612-16617. (Pubitemid 39557761)
3. Ball NJ, Yohn JJ, Morelli JG, Norris DA, Golitz LE, Hoeffler JP. (1994). Ras mutations in human melanoma: a marker of malignant progression. J Invest Dermatol 102: 285-290.
4. Bastian BC, Olshen AB, LeBoit PE, Pinkel D. (2003). Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol 163: 1765-1770. (Pubitemid 37310008)
5. Bauer J, Bastian BC. (2006). Distinguishing melanocytic nevi from melanoma by DNA copy number changes: comparative genomic hybridization as a research and diagnostic tool. Dermatol Ther 19: 40-49.
6. Brodie C, Steinhart R, Kazimirsky G, Rubinfeld H, Hyman T, Ayres JN et al. (2004). PKCdelta associates with and is involved in the phosphorylation of RasGRP3 in response to phorbol esters. Mol Pharmacol 66: 76-84. (Pubitemid 38822089)
7. Broome Powell M, Gause PR, Hyman P, Gregus J, Lluria-Prevatt M, Nagle R et al. (1999). Induction of melanoma in TPras transgenic mice. Carcinogenesis 20: 1747-1753. (Pubitemid 29410554)
8. Coughlin JJ, Stang SL, Dower NA, Stone JC. (2005). RasGRP1 and RasGRP3 regulate B cell proliferation by facilitating B cell receptor-Ras signaling. J Immunol 175: 7179-7184. (Pubitemid 41713411)
9. Cully M, You H, Levine AJ, Mak TW. (2006). Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 6: 184-192. (Pubitemid 43292562)
10. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky Jr WE et al. (2009). Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41: 544-552.
11. Eckhart L, Bach J, Ban J, Tschachler E. (2000). Melanin binds reversibly to thermostable DNA polymerase and inhibits its activity. Biochem Biophys Res Commun 271: 726-730. (Pubitemid 30444696)
12. Furge KA, Kiewlich D, Le P, Vo MN, Faure M, Howlett AR et al. (2001). Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase. Proc Natl Acad Sci USA 98: 10722-10727. (Pubitemid 32878688)
13. Gao L, Feng Y, Bowers R, Becker-Hapak M, Gardner J, Council L et al. (2006). Ras-associated protein-1 regulates extracellular signal-regulated kinase activation and migration in melanoma cells: two processes important to melanoma tumorigenesis and metastasis. Cancer Res 66: 7880-7888. (Pubitemid 44299150)
14. Gawecka JE, Griffiths GS, Ek-Rylander B, Ramos JW, Matter ML. (2010). R-Ras regulates migration through an interaction with filamin A in melanoma cells. PLoS One 5: e11269.
15. Guo FF, Kumahara E, Saffen D. (2001). A CalDAG-GEFI/Rap1/B-Raf cassette couples M(1) muscarinic acetylcholine receptors to the activation of ERK1/2. J Biol Chem 276: 25568-25581.
16. Haluska FG, Ibrahim N. (2006). Therapeutic targets in melanoma: map kinase pathway. Curr Oncol Rep 8: 400-405. (Pubitemid 44336301)
17. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA. (2003). Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 63: 5198-5202. (Pubitemid 37139827)
18. Houben R, Becker JC, Kappel A, Terheyden P, Brocker EB, Goetz R et al. (2004). Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog 3: 6.
19. Huang HP, Shih YW, Chang YC, Hung CN, Wang CJ. (2008). Chemoinhibitory effect of mulberry anthocyanins on melanoma metastasis involved in the Ras/PI3K pathway. J Agric Food Chem 56: 9286-9293.
20. Ikediobi ON, Davies H, Bignell G, Edkins S, Stevens C, O'Meara S et al. (2006). Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 5: 2606-2612. (Pubitemid 44848987)
21. Ikenoue T, Hikiba Y, Kanai F, Aragaki J, Tanaka Y, Imamura J et al. (2004). Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation. Cancer Res 64: 3428-3435. (Pubitemid 38657914)
22. Ikenoue T, Hikiba Y, Kanai F, Tanaka Y, Imamura J, Imamura T et al. (2003). Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Res 63: 8132-8137. (Pubitemid 37549459)
23. Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F et al. (2004). B-RAF is a therapeutic target in melanoma. Oncogene 23: 6292-6298. (Pubitemid 39215299)
24. Khwaja A, Rodriguez-Viciana P, Wennstrom S, Warne PH, Downward J. (1997). Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J 16: 2783-2793. (Pubitemid 27226215)
25. Lorenzo PS, Beheshti M, Pettit GR, Stone JC, Blumberg PM. (2000). The guanine nucleotide exchange factor RasGRP is a high-affinity target for diacylglycerol and phorbol esters. Mol Pharmacol 57: 840-846. (Pubitemid 30253365)
26. Lorenzo PS, Kung JW, Bottorff DA, Garfield SH, Stone JC, Blumberg PM. (2001). Phorbol esters modulate the Ras exchange factor RasGRP3. Cancer Res 61: 943-949. (Pubitemid 32174409)
27. Oh-hora M, Johmura S, Hashimoto A, Hikida M, Kurosaki T. (2003). Requirement for Ras guanine nucleotide releasing protein 3 in coupling phospholipase C-gamma2 to Ras in B cell receptor signaling. J Exp Med 198: 1841-1851. (Pubitemid 38032117)
28. Ohba Y, Ikuta K, Ogura A, Matsuda J, Mochizuki N, Nagashima K et al. (2001). Requirement for C3G-dependent Rap1 activation for cell adhesion and embryogenesis. Embo J 20: 3333-3341. (Pubitemid 32634341)
29. Oki-Idouchi CE, Lorenzo PS. (2007). Transgenic overexpression of RasGRP1 in mouse epidermis results in spontaneous tumors of the skin. Cancer Res 67: 276-280. (Pubitemid 46142785)
30. Orian-Rousseau V, Morrison H, Matzke A, Kastilan T, Pace G, Herrlich P et al. (2007). Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin. Mol Biol Cell 18: 76-83. (Pubitemid 46066712)
31. Pacold ME, Suire S, Perisic O, Lara-Gonzalez S, Davis CT, Walker EH et al. (2000). Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. Cell 103: 931-943.
32. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM et al. (2003). High frequency of BRAF mutations in nevi. Nat Genet 33: 19-20. (Pubitemid 36068675)
33. Pu Y, Perry NA, Yang D, Lewin NE, Kedei N, Braun DC et al. (2005). A novel diacylglycerol-lactone shows marked selectivity in vitro among C1 domains of protein kinase C (PKC) isoforms alpha and delta as well as selectivity for RasGRP compared with PKCalpha. J Biol Chem 280: 27329-27338. (Pubitemid 41040774)
34. Roberts DM, Anderson AL, Hidaka M, Swetenburg RL, Patterson C, Stanford WL et al. (2004). A vascular gene trap screen defines RasGRP3 as an angiogenesis-regulated gene required for the endothelial response to phorbol esters. Mol Cell Biol 24: 10515-10528. (Pubitemid 39603114)
35. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ et al. (1994). Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370: 527-532. (Pubitemid 24264918)
36. Sarkisian CJ, Keister BA, Stairs DB, Boxer RB, Moody SE, Chodosh LA. (2007). Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol 9: 493-505. (Pubitemid 46696530)
37. Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL et al. (2003). Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 63: 756-759. (Pubitemid 36231971)
38. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. (1997). Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88: 593-602. (Pubitemid 27152402)
39. Stark M, Hayward N. (2007). Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res 67: 2632-2642. (Pubitemid 46548950)
40. Stone JC. (2006). Regulation of Ras in lymphocytes: get a GRP. Biochem Soc Trans 34: 858-861. (Pubitemid 44796438)
41. Stope MB, Vom Dorp F, Szatkowski D, Bohm A, Keiper M, Nolte J et al. (2004). Rap2B-dependent stimulation of phospholipase C-epsilon by epidermal growth factor receptor mediated by c-Src phosphorylation of RasGRP3. Mol Cell Biol 24: 4664-4676. (Pubitemid 38668034)
42. Sumimoto H, Miyagishi M, Miyoshi H, Yamagata S, Shimizu A, Taira K et al. (2004). Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene 23: 6031-6039. (Pubitemid 39178855)
43. Sutlovic D, Definis Gojanovic M, Andelinovic S, Gugic D, Primorac D. (2005). Taq polymerase reverses inhibition of quantitative real time polymerase chain reaction by humic acid. Croat Med J 46: 556-562. (Pubitemid 41248179)
44. Suzuki T, Shen H, Akagi K, Morse HC, Malley JD, Naiman DQ et al. (2002). New genes involved in cancer identified by retroviral tagging. Nat Genet 32: 166-174. (Pubitemid 34977213)
45. Takayama H, LaRochelle WJ, Sharp R, Otsuka T, Kriebel P, Anver M et al. (1997). Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci USA 94: 701-706.
46. Teixeira C, Stang SL, Zheng Y, Beswick NS, Stone JC. (2003). Integration of DAG signaling systems mediated by PKC-dependent phosphorylation of RasGRP3. Blood 102: 1414-1420. (Pubitemid 36988051)
47. Tuveson DA, Shaw AT, Willis NA, Silver DP, Jackson EL, Chang S et al. (2004). Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5: 375-387. (Pubitemid 38482073)
48. van Elsas A, Zerp S, van der Flier S, Kruse-Wolters M, Vacca A, Ruiter DJ et al. (1995). Analysis of N-ras mutations in human cutaneous melanoma: tumor heterogeneity detected by polymerase chain reaction/single-stranded conformation polymorphism analysis. Recent Results Cancer Res 139: 57-67.
49. Wang D, Yang W, Du J, Devalaraja MN, Liang P, Matsumoto K et al. (2000). MGSA/GRO-mediated melanocyte transformation involves induction of Ras expression. Oncogene 19: 4647-4659.
50. Wu H, Goel V, Haluska FG. (2003). PTEN signaling pathways in melanoma. Oncogene 22: 3113-3122. (Pubitemid 36713763)
51. Yamashita S, Mochizuki N, Ohba Y, Tobiume M, Okada Y, Sawa H et al. (2000). CalDAG-GEFIII activation of Ras, R-ras, and Rap1. J Biol Chem 275: 25488-25493.
52. Yang D, Kedei N, Li L, Tao J, Velasquez JF, Michalowski AM et al. (2010). RasGRP3 contributes to formation and maintenance of the prostate cancer phenotype. Cancer Res 70: 7905-7917.
53. Zheng H, Gao L, Feng Y, Yuan L, Zhao H, Cornelius LA. (2009). Down-regulation of Rap1GAP via promoter hypermethylation promotes melanoma cell proliferation, survival, and migration. Cancer Res 69: 449-457.
54. Zheng Y, Liu H, Coughlin J, Zheng J, Li L, Stone JC. (2005). Phosphorylation of RasGRP3 on threonine 133 provides a mechanistic link between PKC and RAS signaling systems in B cells. Blood 105: 3648-3654. (Pubitemid 40628212)